{"id":3844,"date":"2018-12-17T14:36:02","date_gmt":"2018-12-17T14:36:02","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/"},"modified":"2018-12-17T14:36:02","modified_gmt":"2018-12-17T14:36:02","slug":"nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/","title":{"rendered":"Nanexa skriver ytterligare samarbetsavtal f\u00f6r utv\u00e4rdering av PharmaShell\u00ae"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><span><strong><\/strong><\/span><\/p>\n<\/div>\n<p><span>Ett svenskt biotechbolag har idag skrivit avtal med Nanexa om att utv\u00e4rdera PharmaShell\u00aesom drug delivery-teknologi f\u00f6r en specific substans men ocks\u00e5 som drug delivery-plattform f\u00f6r biotechbolagets utvecklingsportf\u00f6lj. Utv\u00e4rderingen regleras av ett\u00a0\u201dMaterial Transfer and Feasibility study agreement\u201d\u00a0och startar inom kort.<\/span><\/p>\n<p><span>Utv\u00e4rderingsarbetet inleds med\u00a0in vitro-studier och planer finns att ta formuleringen vidare in i prekliniska djurf\u00f6rs\u00f6k. Om utv\u00e4rderingen faller v\u00e4l ut kommer resultaten ligga till grund f\u00f6r f\u00f6rhandling om ett ut\u00f6kat kommersiellt avtal r\u00f6rande PharmaShell\u00ae.<\/span><\/p>\n<p><span>I det nu \u00f6verenskomna samarbetet erh\u00e5ller Nanexa \u00f6verenskomna mindre betalningar vid leverans av\u00a0in vitro-resultat samt vid leverans av material till en\u00a0in vivo-studie. Det svenska biotechbolaget som Nanexa tecknat avtal med bekostar \u00e4ven\u00a0in vivo-studien\u00a0som planeras inom ramen f\u00f6r utv\u00e4rderingen.<\/span><\/p>\n<p><span>Nanexas VD David Westberg kommenterar:<\/span><\/p>\n<p><span>Det \u00e4r v\u00e4ldigt roligt att detta fram\u00e5triktade biotechbolag valt att utv\u00e4rdera Nanexas teknologi PharmaShell\u00ae\u00a0som en m\u00f6jlig plattform f\u00f6r deras l\u00e4kemedelsutveckling. Jag bed\u00f6mer att bolaget har en mycket intressant utvecklingsportf\u00f6lj och ser att PharmaShell\u00ae-teknologin kan passa mycket v\u00e4l in i den m\u00e5ls\u00e4ttning bolaget har.<\/span><\/p>\n<p><span>Extra gl\u00e4djande \u00e4r att vi sedan i fredagskv\u00e4ll slutit avtal med inte mindre \u00e4n tre bolag f\u00f6r att utv\u00e4rdera PharmaShell\u00ae\u00a0(se tidigare pressmeddelanden under dagen). Jag har redan tidigare kommunicerat att vi haft ett antal p\u00e5g\u00e5ende diskussioner och att nu tre av dessa signerats i stort sett samma dag \u00e4r fantastiskt och ett stort steg f\u00f6r Nanexa. Vi kommer g\u00e5 in i 2019 i en helt ny situation med flera sp\u00e4nnande m\u00f6jligheter i dessa partnersamarbeten med m\u00f6jlighet till f\u00f6rl\u00e4ngning in i skarp produktutveckling.<\/span><\/p>\n<p><span>F\u00f6r mer information kontakta:<br \/>David Westberg\u00a0\u2013\u00a0VD, Nanexa AB (publ)\u00a0Telefon: 0709 &#8211; 42 83 03<br \/>E-post: david.westberg@nanexa.se www.nanexa.com<\/span><\/p>\n<p><span>Denna information \u00e4r s\u00e5dan information som Nanexa AB \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 17 december, 2018.<\/span><\/p>\n<p><span>Om Nanexa AB (publ)<\/span><\/p>\n<p><span>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae\u00a0som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae\u00a0har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/span><\/p>\n<p><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<p><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/mb.cision.com\/Main\/12591\/2702494\/964726.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">L\u00e4s som pdf<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<\/p>\n<p>Ett svenskt biotechbolag har idag skrivit avtal med Nanexa om att utv\u00e4rdera PharmaShell\u00aesom drug delivery-teknologi f\u00f6r en specific substans men ocks\u00e5 som drug delivery-plattform f\u00f6r biotechbolagets utvecklingsportf\u00f6lj.<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3844","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-ci-sales_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-sales-order_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa skriver ytterligare samarbetsavtal f\u00f6r utv\u00e4rdering av PharmaShell\u00ae - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa skriver ytterligare samarbetsavtal f\u00f6r utv\u00e4rdering av PharmaShell\u00ae - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Ett svenskt biotechbolag har idag skrivit avtal med Nanexa om att utv\u00e4rdera PharmaShell\u00aesom drug delivery-teknologi f\u00f6r en specific substans men ocks\u00e5 som drug delivery-plattform f\u00f6r biotechbolagets utvecklingsportf\u00f6lj.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\\\/\",\"name\":\"Nanexa skriver ytterligare samarbetsavtal f\u00f6r utv\u00e4rdering av PharmaShell\u00ae - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2018-12-17T14:36:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa skriver ytterligare samarbetsavtal f\u00f6r utv\u00e4rdering av PharmaShell\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa skriver ytterligare samarbetsavtal f\u00f6r utv\u00e4rdering av PharmaShell\u00ae - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa skriver ytterligare samarbetsavtal f\u00f6r utv\u00e4rdering av PharmaShell\u00ae - Nanexa AB","og_description":"Ett svenskt biotechbolag har idag skrivit avtal med Nanexa om att utv\u00e4rdera PharmaShell\u00aesom drug delivery-teknologi f\u00f6r en specific substans men ocks\u00e5 som drug delivery-plattform f\u00f6r biotechbolagets utvecklingsportf\u00f6lj.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/","name":"Nanexa skriver ytterligare samarbetsavtal f\u00f6r utv\u00e4rdering av PharmaShell\u00ae - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2018-12-17T14:36:02+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-skriver-ytterligare-samarbetsavtal-for-utvardering-av-pharmashell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa skriver ytterligare samarbetsavtal f\u00f6r utv\u00e4rdering av PharmaShell\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}